Title:
HETEROCYCLIC COMPOUND THAT ACTS ON G12D MUTANT KRAS PROTEIN
Document Type and Number:
WIPO Patent Application WO/2024/019103
Kind Code:
A1
Abstract:
Provided is a compound that is effective as an active ingredient in a therapeutic pharmaceutical composition for pancreatic cancer. Having studied compounds that are effective as active ingredients in a therapeutic pharmaceutical composition for pancreatic cancer, the inventors found that the heterocyclic compound shown in formula (I) has excellent degradation-inducing action in the G12D mutant KRAS protein and/or inhibitory activity for G12D mutant KRAS and can be used as a therapeutic drug for pancreatic cancer, and thus completed the present invention. The heterocyclic compound according to the present invention or salts thereof can be used as a therapeutic drug for pancreatic cancer.
Inventors:
YOSHINARI TOMOHIRO (JP)
WATANABE HIDEYUKI (JP)
ISHIOKA HIROKI (JP)
KAWAMINAMI EIJI (JP)
KAWAGUCHI KENICHI (JP)
TAKAHASHI FUMIE (JP)
KAMIKUBO TAKASHI (JP)
IMAIZUMI TOMOYOSHI (JP)
MORIKAWA TAKAHIRO (JP)
HAMAGUCHI HISAO (JP)
KURAMOTO KAZUYUKI (JP)
INAMI HIROSHI (JP)
NAGASHIMA TAKEYUKI (JP)
INAMURA KOHEI (JP)
WATANABE HIDEYUKI (JP)
ISHIOKA HIROKI (JP)
KAWAMINAMI EIJI (JP)
KAWAGUCHI KENICHI (JP)
TAKAHASHI FUMIE (JP)
KAMIKUBO TAKASHI (JP)
IMAIZUMI TOMOYOSHI (JP)
MORIKAWA TAKAHIRO (JP)
HAMAGUCHI HISAO (JP)
KURAMOTO KAZUYUKI (JP)
INAMI HIROSHI (JP)
NAGASHIMA TAKEYUKI (JP)
INAMURA KOHEI (JP)
Application Number:
PCT/JP2023/026522
Publication Date:
January 25, 2024
Filing Date:
July 20, 2023
Export Citation:
Assignee:
ASTELLAS PHARMA INC (JP)
International Classes:
C07D401/14; A61K31/496; A61K31/4995; A61K31/513; A61K31/517; A61P1/18; A61P35/00; C07D405/14; C07D487/08; C07D519/00
Domestic Patent References:
| WO2019195609A2 | 2019-10-10 | |||
| WO2021051034A1 | 2021-03-18 | |||
| WO2017172979A1 | 2017-10-05 | |||
| WO2015160845A2 | 2015-10-22 |
Foreign References:
| US20180015087A1 | 2018-01-18 |
Attorney, Agent or Firm:
YAMAMOTO, Osamu et al. (JP)
Download PDF: